Regulated transcription of protein encoding genes in eukaryotes by RNA polymerase II requires a multitude of factors including transcriptional activators that bind DNA to enhance transcription in a gene-specific manner and basal factors (transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) that are required for promoter-specific initiation (for reviews, see refs. 1 and 2). Of these factors, TFIID specifically recognizes and binds to "TATA boxes" found within many promoters. We now know that TFIID is a multisubunit complex containing the TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs; refs. 3-5; for review, see ref. 6). It was found that recombinant TBP can substitute for TFIID in directing basal levels of transcription in vitro (7, 8). However, transcription driven by TBP alone is not responsive to transcriptional activators. Thus TAFs appear to represent a unique class of factors in that they are not necessary to direct basal transcription from TATA-containing promoters but are required for transcriptional activation.
served with Drosophila TAF1I40, hTAF]a32 interacts with the C-terminal 39-amino acid activation domain of the acidic transactivator viral protein 16 (VP16) as well as with the general transcription factor TFIIB. Moreover, a partial recombinant TFIID complex containing hTAFH32 was capable of mediating in vitro transcriptional activation by the VP16 activation domain. These findings indicate that specific activator-coactivator interactions have been conserved between human and Drosophila and provide additional support for the function of these interactions in mediating transcriptional activation.
Regulated transcription of protein encoding genes in eukaryotes by RNA polymerase II requires a multitude of factors including transcriptional activators that bind DNA to enhance transcription in a gene-specific manner and basal factors (transcription factors TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) that are required for promoter-specific initiation (for reviews, see refs. 1 and 2). Of these factors, TFIID specifically recognizes and binds to "TATA boxes" found within many promoters. We now know that TFIID is a multisubunit complex containing the TATA binding protein (TBP) and at least eight TBP-associated factors (TAFs; refs. 3-5; for review, see ref. 6 ). It was found that recombinant TBP can substitute for TFIID in directing basal levels of transcription in vitro (7, 8) . However, transcription driven by TBP alone is not responsive to transcriptional activators. Thus TAFs appear to represent a unique class of factors in that they are not necessary to direct basal transcription from TATA-containing promoters but are required for transcriptional activation.
This observation (8) led to the proposal that some of the TAFs in the TFIID complex would directly contact activators and basal factors thereby mediating signals from activators to the basal transcription machinery and, furthermore, that different classes of activation domains (such as acidic, glutaminerich, proline-rich, or isoleucine-rich) would contact distinct TAFs within the TFIID complex. This laboratory has now obtained (9) (10) (11) (12) (13) evidence for a number of interactions between TAFs and transcriptional activators and between TAFs and other basal transcription factors. Direct evidence for the function of TAFs as coactivators was obtained when recom-
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binant TAFs and TBP were assembled into partial TFIID complexes that could support transcriptional activation in vitro by a number of activators (11, 12) . For example, a partial complex consisting of the 250-kDa subunit of human TFIID (hTAFI1250), Drosophila (d) TBP, dTAFI150, and dTAFlillO can replace a crude TFIID fraction in mediating transcriptional activation by Spl (11) . However, all of our studies examining the activity of partial TFIID complexes have used Drosophila coactivators. It was therefore important to test the generality of the specific TAF-activator interactions in mediating transcriptional activation by using the human subunits.
We have previously reported the cloning and characterization of dTAF1140 (10) . This 40-kDa subunit of dTFIID was found to specifically interact with the C-terminal 39-amino acid activation domain of viral protein 16 (VP16) (termed VP16c) and with the basal transcription factor TFIIB. Here we extend our analysis of coactivators for VP16 by cloning and characterizing the human homologue of dTAFI40, hTAFI132.J
We have expressed recombinant hTAF1132 in several forms and have tested their ability to interact with the activation domains of VP16 and with TFIIB. In addition, we have assembled partial TFIID complexes consisting of recombinant hTBP and hTAFs (including hTAF1132) and tested the ability of these complexes to mediate transcriptional activation in vitro by a GAL4-VP16c fusion protein. Our studies demonstrate a functional conservation between dTAF,140 and hTAF1132 as coactivators for the C-terminal VP16 activation domain and provide further support for the role of TAFs in potentiating transcriptional activation.
MATERIALS AND METHODS
Purification of hTFIID and Cloning of hTAFH32. The TFIID fraction was purified from HeLa nuclear extracts by phosphocellulose chromatography followed by immunopurification on an anti-TBP column. Antibody affinity columns were made with .200 jig of affinity-purified polyclonal TBP antibodies crosslinked to 200 ,ul of protein A-Sepharose with dimethyl pimelimidate (ref. 14, pp. 522-523). The phosphocellulose TFIID fraction (1 M KC1 eluate) was passed over a mock column of protein A-Sepharose treated with crosslinker to reduce nonspecific background. The flowthrough of the mock column was then loaded on the anti-TBP column multiple times. After stringent washing, TFIID was eluted with 50 mM glycine (pH 2.5) containing 0.15 M NaCl and then subjected to reversed-phase HPLC on a C8 column as described (9) . Peak fractions were collected and digested with the Abbreviations: GST (10) . In general, each assay contained 1 ,tg of GST fusion protein immobilized on 10 pl of glutathione-Sepharose beads (Pharmacia). Target proteins (100-200 ng) were incubated with GST and GST fusion protein beads generally for 1-2 h in TGEM buffer containing 0.1% Nonidet P-40 and NaCl at concentrations noted in the figure legends. The incubations were performed in 100 pl at 4°C with constant nutation (orbital mixing). After the incubation, the beads were washed at least four times with 10-15 bead volumes of buffer (same as load buffer). Protein was eluted from the beads in SDS sample buffer, resolved by SDS/PAGE, and blotted to a nitrocellulose membrane. Membranes were probed as described in the figures.
Assembly of Partial TFIID Complexes. Partial TFIID complexes were assembled as described by Chen et at (11) . A hemagglutinin (HA)-epitope-tagged version of hTAF11250 was expression in SF9 cells from a recombinant baculovirus as described (11) . hTAFII70 was expressed in E. coli by using the pET expression system. hTBP was expressed in E. coli and purified to homogeneity as described (16) . His-hTAF,132 (N181) was expressed in E. coli and purified over nitrilotriacetic acid-agarose (Qiagen, Chatsworth, CA), followed by elution with 500 mM imidazole and dialysis. The complexes were assembled on protein A-Sepharose beads to which anti-HA antibodies had been crosslinked. Each assembly reaction mixture contained 20 ul of anti-HA beads and was incubated first with SF9-cell extract containing recombinant HAhTAFI1250 (40 ,ug) in TGEMC (TGEM containing 1% CHAPS) containing 0.4 M NaCl. The mixture was nutated for 4 h at 4°C. The beads were then washed twice with 200 ,ul of TGEMC containing 1.0 M NaCl and four times with TGEMC containing 0.2 M NaCl. The HA-TAF11250 beads were then used for the assembly of the remaining factors in the following order: (i) hTAF1170 (E. coli sonicate containing '20 ,ug of hTAF,170), (ii) His-hTAF1132(N181) (20 ,g), and (iii) hTBP (20 jig). Each incubation was performed for 4 h at 4°C with constant nutation and was followed by four 200-,ul washes with TGEMC containing 0.2 M NaCl. The complexes were eluted in 100 ,ul of TGEMC containing 0.2 M NaCl and HA-epitope peptide at 1 mg/ml. Elutions were performed for 1.5 h at 4°C followed by a 20-min incubation at room temperature. The eluted material was stored in small aliquots at -80°C.
In Vitro Transcription. Transcription reactions were performed in a partially fractionated HeLa system. Briefly, a HeLa nuclear extract was chromatographed over phosphocellulose as described (17 (28) in a pSP72 backbone. GAL4-VP16c and GAL-(1-147) were expressed in E. coli, purified as described (10) , and included in transcription reaction mixtures (25 ng) where indicated. The final reaction conditions and incubation times were as described (19) . RESULTS 
AND DISCUSSION
Molecular Cloning of hTAF,132. hTFIID was purified from HeLa-cell nuclear extracts by conventional chromatography and anti-hTBP affinity chromatography (4, 20) . Two hundred liters of HeLa cells yielded ' Consequently, this subunit of hTFIID has been named hTAF1132.
Comparison of hTAFI32 to dTAF1140 shows strong conservation in an N-terminal region and at the far C terminus (Fig. 1) . However, the C-terminal halves of the Drosophila and human proteins are highly divergent. Throughout the entire length of these two proteins, there is 40% identity and 48% sequence similarity. A higher degree of similarity (57% identity and 69% similarity) is seen in the N-terminal 143 aa. Data base searches were performed by using BLASTP (21 (10, 23, 24, 26) to activate transcription in vitro and in vivo. As shown in Fig. 3B , GSThTAFI32 bound both GAL4-VP16NC and GAL4-VP16c but did not bind GAL4-(1-147) and GAL4-VP16N. All of the hybrid activators failed to bind control GST beads. These results correspond exactly to those found for dTAF1140 (10) (Fig. 3C) . Apparently, much of the nonconserved C termini of hTAF1132 and dTAF,140 are dispensable for binding VP16, whereas the conserved N-terminal region contains the interface important for recognition of VP16c.
hTAF,132 Interacts with hTAFOO7O and TFIIB. Interactions between dTAF1140 and two additional proteins, dTAF1160 (27) and the basal transcription factor TFIIB (10), have been detected. The first of these interactions appears to be responsible for recruitment of dTAF1140 to the TFIID complex, and the latter of the interactions may play a functional role in mediating transcriptional activation by VP16. As shown in Fig.  4A , immobilized His-TAF1132(N181) can specifically retain hTAFOO7O from an E. coli extract. We believe that this interaction between hTAF1132 and hTAF1170 may actually function to recruit hTAF1132 to the TFIID complex (see below).
To test for interactions between hTAF,132 and TFIIB, we performed an affinity chromatography experiment similar to those described above. Immobilized GST-hTAFII32 resin was incubated with hTFIIB. Specifically bound proteins were resolved by SDS/PAGE, transferred to nitrocellulose, and probed with anti-TFIIB serum. As shown in Fig. 4B , hTFIIB binds efficiently to GST-hTAF1132 but no detectable TFIIB bound to control GST beads. Thus the TFIIB interaction domain also appears to be conserved between hTAFI32 and dTAF1140. Moreover, these protein-protein interaction studies establish that several sets of interactions including TAF-TAF, TAF-basal factor, and TAF-activator contacts are conserved between Drosophila and humans.
A Partial Recombinant TFIID Complex Containing hTAFI32 Mediates Activation by GAL4-VP16c. The reconstitution of partial TFIID complexes that are functional in mediating transcriptional activation by specific activators has been reported (11, 12) . These complexes were assembled by using immobilized HA-hTAFII250 as a building block upon which purified recombinant dTBP and dTAFs were added. However, the (27) and hTAF1132 (Fig. 4A) . We thus set out to assemble complexes from these four subunits of hTFIID.
The four recombinant TFIID subunits hTBP, HA-hTAF,1250, hTAF,170, and His-hTAFI132(N181) were expressed and assembled into three partial TFIID complexes. All three complexes contained HA-hTAF11250 and hTBP. The triplex contained in addition hTAF1170, while the quadruplex included hTAFI70 and His-hTAF8832(N181). A silver-stained gel of the eluted complexes revealed that HA-hTAFI1250 and hTBP were present at similar levels in all three complexes (Fig . In vitro transcriptional activation by GAL4-VP16c was tested in a TFIID-dependent system using a TFIID fraction (lanes 1 and 2), the duplex (lanes 3 and 4), the triplex (lanes 5 and 6) , and the quadruplex (lanes 7 and 8). In addition, the quadruplex was tested for GAL4-(1-147) transcriptional activation (lanes 9 and 10). The data shown are from a single representative experiment, but lanes 1 and 2 were exposed to film three times longer than lanes 3-10. tion assays, the triplex does not appear to be sufficient for eliciting efficient activation. Perhaps hTAF1132 and hTAF1170 act cooperatively as coactivators for VP16c, or alternatively, hTAF1132 may stabilize the hTAF,170-hTAF,1250 interaction in the partial complex. In contrast, the duplex was completely unable to support activation by GAL4-VP16c (Fig. 5B, lanes 3-6) . As expected, GAL4-(1-147) does not stimulate transcription with the quadruplex (lanes 9 and 10). These experiments provide direct evidence that hTAF1132 or a complex containing both hTAF1170 and hTAFt132 can function as a coactivator for mediating transcriptional activation by GAL4-VP16c.
We have documented (10) an interaction between dTAF1140 and the activator GAL4-VP16, and at that time, we proposed that dTAFI840 might function as a coactivator for VP16. Since VP16 is a human herpes virus transactivator, we felt it was important to identify the human homologue of dTAF,140.
Here we have extended our analysis of coactivators for VP16 by cloning and characterizing hTAF1132. We have shown that the binding interactions with VP16 and TFIIB are conserved between dTAF,140 and hTAFt132. More importantly, we have now found that hTAF1832 can function as a coactivator for the VP16c activation domain. Interestingly, the activation domain of the tumor suppressor p53 interacts with hTAFI170 and hTAF1132, as well as their Drosophila homologues, and these interactions seem to play a role in mediating transcriptional activation (12) . These findings with the VP16c and p53 activation domains add strong support to the notion that classes of activators target selected TAFs in the TFIID complex to direct transcriptional activation.
